Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking

Executive Summary

FDA's approval of Vanda's Fanapt (iloperidone) May 6 means that the bar for new atypical antipsychotic approvals may not be as high as it seemed 10 months ago, when FDA's "not approvable" letter on iloperidone requested an additional comparative trial
Advertisement

Related Content

Antipsychotic Drugs Are Medco's New Personalized Medicine Target
Antipsychotic Drugs Are Medco's New Personalized Medicine Target
FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt
Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt
Support For Serdolect In Specific Patients, But Panel Can’t Define Population
Proxy War-Front Latest: Amylin, Vanda Rocked By Dissident Shareholders
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future

Topics

Advertisement
UsernamePublicRestriction

Register

PS051053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel